Mutual Recognition Agreements (MRAs) are agreements between two trading partners on the elimination of technical barriers to trade. This is one of the issues that will be important in the trade negotiations between the UK and the EU. This would make life much more difficult for British manufacturers, as they would be forced to have products certified by EU authorities before they could export them to the continent. The European Commission`s approach to the UK`s ripper is different from the one it has negotiated with other countries. The MRA with Israel is an agreement on the compliant evaluation and acceptance of industrial products (ACAA). This is a specific type of MRA based on the alignment of the legal system and infrastructure of the country concerned with that of the EU. There are several other examples of mutual recognition of regulations, including the 2004 EU-US MRA for marine equipment, the 1998 Trans-European Agreement on Mutual Recognition between Australia and New Zealand (TTMRA) and the 2002 EU-Switzerland MRA. If the EU refuses to negotiate a similar system of mutual recognition with the UK, it could violate the most-favoured-nation (MFN) obligation under World Trade Organisation (WTO) law. Most dominations are a non-discrimination rule that requires that any benefit granted to goods originating in one country be granted to like goods originating in other countries.
The Mutual Recognition Agreement (MRA) between the FDA and the European Union allows drug inspectors to rely on information from drug inspections conducted within each other`s borders. Under the Food and Drug Administration Safety and Innovation Act, enacted in 2012, the FDA has the authority to enter into agreements to recognize drug inspections by foreign regulatory agencies if it determines that those agencies are able to conduct inspections that comply with U.S. requirements. The FDA and the EU have been working together since May 2014 to assess how they each inspect drug manufacturers and to assess the risks and benefits of mutual recognition of drug inspections. NIST is the U.S. designating authority for MRMs. NIST is responsible for designating qualified U.S. CAOs for our various MRA partners. NIST receives, reviews and processes applications from CAOs seeking recognition from our MRA partners. MRA partner regulatory bodies formally recognize CACs for their specific technical regulations/standards and/or certification requirements. . .